Accordingly, the phase 1/1b clinical trials conducted on refractory renal and non-small cell lung cancer patients reported that A2AR antagonism showed antitumor activity with clinical responses, even in patients resistant or refractory to prior anti-PD-1/PD-L1 treatment (56, 77). This evidence concerns the gene CD274 and non-small cell lung carcinoma.